- Home
- Guidelines
Guidelines
An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
- 1.00
Published:
Learning objectives
- Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
- Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
- Discuss long-term management strategies for patients receiving myosin inhibitor therapy
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
Changing Paradigms in Therapy to Unmet Needs
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice